New oral drug chidamide tested for Hard-to-Treat bone marrow disorder
NCT ID NCT07616336
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug chidamide (Tucidinostat) in 15 people aged 60 or older with intermediate-to-high-risk myelodysplastic syndromes (MDS), a bone marrow disorder that can lead to leukemia. Participants take chidamide orally twice a week for up to 3 months. The study aims to see if the drug can improve blood counts and bone marrow health, and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Chidamide (also called Tucidinostat), an oral drug
- What this could lead to
- If successful, this could point toward a new treatment option for people with intermediate-to-high-risk myelodysplastic syndromes who have few choices.
- What could go wrong
- This is a very small, early-phase trial with only 15 people. It may not show enough benefit or could have side effects that limit its use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERMEDIATE-TO-HIGH-RISK MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital (Xiamen), Fudan University
Xiamen, Fujian, 361015, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- Can engineered immune cells outsmart Hard-to-Treat blood cancers?
- Can a new drug offer hope for blood cancers when chemo fails?
- Can a Gene-Targeted pill turn the tide against a rare blood cancer?